|Supplied by:||European Collection of Authenticated Cell Cultures (ECACC)|
|Culture Type:||Cell line|
|Collection:||ECACC General Collection|
|Cell Line Name:||A2780ADR|
|Citation Guidance:||If use of this culture results in a scientific publication, it should be cited in the publication as: A2780ADR (ECACC 93112520)|
|Keywords:||Human Caucasian ovarian carcinoma|
|Cell Line Description:||The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line (ECACC catalogue no. 93112519) to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastine. To retain resistance adriamycin has to be added to the media. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. Together with the cisplatin-resistant variant A2780cis these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer.|
|Tissue of Origin:||ovary|
Unless specified otherwise, at the European Collection of Authenticated Cell Cultures (ECACC) we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines. ACDP = Advisory Committee on Dangerous Pathogens (UK)
All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country.
ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Hyperlinks to MSDS documents:
Frozen cell cultures Material Safety Data Sheet
Growing cell cultures Material Safety Data Sheet
Nucleic acids derived from cell cultures Material Safety Data Sheet
|Subculture Routine:||Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 2-4 x10,000cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C.|
|Culture Medium:||RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS); treatment with 10E-7 M adriamycin at least once a week.|
|Depositor:||Dr T H Ward, Cell Culture Unit, Patterson Laboratories, Christie Hospital, Manchester|
|References:||Proc Amer Assoc Cancer Res 1984;25:336; Seminars in Oncology 1984;11:285|
|Additional Bibliography:||Not specified|
|Patents:||None specified by Depositor|
|Release Conditions:||Yes - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' form|
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.
Please confirm your country of origin from the list below.